The genetics of myelodysplastic syndrome: From clonal haematopoiesis to secondary leukaemia

Nature Reviews Cancer

Volumn 17, Issue 1, 2017, Pages 5-19

  Sperling, Adam S ^a   Gibson, Christopher J ^a   Ebert, Benjamin L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COHESIN; PROTEIN P53; TRANSCRIPTION FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER GROWTH; CANCER PROGNOSIS; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME DELETION 5; CLONAL EVOLUTION; CYTOGENETICS; DISEASE CLASSIFICATION; DNA METHYLATION; EPIGENETICS; GENE MUTATION; HEMATOPOIESIS; HISTONE MODIFICATION; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SPLICING; SCORING SYSTEM; ACUTE MYELOID LEUKEMIA; CELL CLONE; GENETICS; PHYSIOLOGY;

CLONAL EVOLUTION; CLONE CELLS; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES;

EID: 84994796883     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.112     Document Type: Review

References (200)

1. Arber, D. A., et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 127, 2391-2405 (2016
2. Liew, E., & Owen, C. Familial myelodysplastic syndromes: a review of the literature. Haematologica 96, 1536-1542 (2011
3. Cogle, C. R. Incidence and burden of the myelodysplastic syndromes. Curr. Hematol. Malignancy Rep. 10, 272-281 (2015
4. Ma, X., Does, M., Raza, A., & Mayne, S. T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109, 1536-1542 (2007
5. Sekeres, M. A. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J. Natl Compr. Canc. Netw. 9, 57-63 (2011
6. Greenberg, P. L., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454-2465 (2012
7. Kantarjian, H., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113, 1351-1361 (2008
8. Malcovati, L., et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 96, 1433-1440 (2011
9. Bejar, R., et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496-2506 (2011
10. Bejar, R., et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 30, 3376-3382 (2012
11. Woll, P. S., et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 25, 794-808 (2014
12. Jaiswal, S., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488-2498 (2014
13. Miyamoto, T., Weissman, I. L., & Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc. Natl Acad. Sci. USA 97, 7521-7526 (2000
14. Nilsson, L., et al. Involvement and functional impairment of the CD34+CD38-Thy 1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 100, 259-267 (2002
15. Nilsson, L., et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 96, 2012-2021 (2000
16. Odejide, O., et al. A targeted mutational landscape of angioimmunoblastic T cell lymphoma. Blood 123, 1293-1296 (2014
17. Quivoron, C., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25-38 (2011
18. Steensma, D. P. Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin. Proc. 90, 969-983 (2015
19. Busque, L., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179-1181 (2012
20. Xie, M., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472-1478 (2014
21. Genovese, G., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477-2487 (2014
22. Steensma, D. P., et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9-16 (2015
23. Cargo, C. A., et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood 126, 2362-2365 (2015
24. Kwok, B., et al. MDS-Associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 126, 2355-2361 (2015
25. Haferlach, T., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241-247 (2014
26. Papaemmanuil, E., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616-3627 (2013
27. Hughes, A. E., et al. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet. 10, e1004462 (2014
28. Lindsley, R. C., et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125, 1367-1376 (2015
29. Corces-Zimmerman, M. R., Hong, W. J., Weissman, I. L., Medeiros, B. C., & Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl Acad. Sci. USA 111, 2548-2553 (2014
30. Murphy, D. M., et al. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia 27, 2077-2081 (2013
31. Takahashi, K., et al. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27, 2081-2083 (2013
32. Welch, J. S., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012
33. Gerstung, M., et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat. Commun. 6, 5901 (2015
34. Kon, A., et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat. Genet. 45, 1232-1237 (2013
35. Bejar, R., et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J. Clin. Oncol. 32, 2691-2698 (2014
36. Ortmann, C. A., et al. Effect of mutation order on myeloproliferative neoplasms. N. Engl. J. Med. 372, 601-612 (2015
37. Jeromin, S., et al. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica 100, e125-e127 (2015
38. Malcovati, L., et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126, 233-241 (2015
39. Ding, L., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012
40. Garg, M., et al. Profiling of somatic mutations in acute myeloid leukemia with FLT3 ITD at diagnosis and relapse. Blood 126, 2491-2501 (2015
41. Jan, M., et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl Med. 4, 149ra118 (2012
42. Shlush, L. I., et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328-333 (2014
43. Klco, J. M., et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 314, 811-822 (2015
44. Walter, M. J., et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27, 1275-1282 (2013
45. Yoshizato, T., et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N. Engl. J. Med. 373, 35-47 (2015
46. Alexandrov, L. B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
47. Greenman, C., et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007
48. Colla, S., et al. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27, 644-657 (2015
49. Lawrence, M. S., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014
50. Inoue, D., Bradley, R. K., & Abdel-Wahab, O. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes Dev. 30, 989-1001 (2016
51. Graubert, T. A., et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 44, 53-57 (2012
52. Papaemmanuil, E., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384-1395 (2011
53. Yoshida, K., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69 (2011
54. Conte, S., et al. Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. Br. J. Haematol. 171, 478-490 (2015
55. Darman, R. B., et al. Cancer-Associated SF3B1 hotspot mutations induce cryptic 3' splice site selection through use of a different branch point. Cell Rep. 13, 1033-1045 (2015
56. Kim, E., et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617-630 (2015
57. Ilagan, J. O., et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 25, 14-26 (2015
58. Przychodzen, B., et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 122, 999-1006 (2013
59. Yang, L., Rau, R., & Goodell, M. A. DNMT3A in haematological malignancies. Nat. Rev. Cancer 15, 152-165 (2015
60. Ley, T. J., et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424-2433 (2010
61. Walter, M. J., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25, 1153-1158 (2011
62. Ko, M., et al. TET proteins and 5 methylcytosine oxidation in hematological cancers. Immunol. Rev. 263, 6-21 (2015
63. Tahiliani, M., et al. Conversion of 5 methylcytosine to 5 hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935 (2009
64. Lorsbach, R. B., et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17, 637-641 (2003
65. Ono, R., et al. LCX, leukemia-Associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11) (q22;q23). Cancer Res. 62, 4075-4080 (2002
66. Okano, M., Xie, S., & Li, E. Cloning and characterization of a family of novel mammalian DNA (cytosine 5) methyltransferases. Nat. Genet. 19, 219-220 (1998
67. Kallin, E. M., et al. Tet2 facilitates the derepression of myeloid target genes during CEBPα-induced transdifferentiation of pre B cells. Mol. Cell 48, 266-276 (2012
68. Rasmussen, K. D., et al. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev. 29, 910-922 (2015
69. Yamazaki, J., et al. TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor-binding sites in chronic myelomonocytic leukemia. Cancer Res. 75, 2833-2843 CAN 14 0739 (2015
70. Dang, L., et al. Cancer-Associated IDH1 mutations produce 2 hydroxyglutarate. Nature 465, 966 (2010
71. Ward, P. S., et al. The common feature of leukemia-Associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2 hydroxyglutarate. Cancer Cell 17, 225-234 (2010
72. Xu, W., et al. Oncometabolite 2 hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30 (2011
73. Losman, J. A., et al. (R)-2 hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621-1625 (2013
74. Lu, C., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474-478 (2012
75. Challen, G. A., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44, 23-31 (2012
76. Zhang, X., et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat. Genet. 48, 1014-1023 (2016
77. Moran-Crusio, K., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11-24 (2011
78. Jeong, M., et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat. Genet. 46, 17-23 (2014
79. Cao, R., et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039-1043 (2002
80. Francis, N. J., Kingston, R. E., & Woodcock, C. L. Chromatin compaction by a polycomb group protein complex. Science 306, 1574-1577 (2004
81. Wang, H., et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 431, 873-878 (2004
82. Sashida, G., et al. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nat. Commun. 5, 4177 (2014
83. Gao, Z., et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol. Cell 45, 344-356 (2012
84. Gearhart, M. D., Corcoran, C. M., Wamstad, J. A., & Bardwell, V. J. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. Mol. Cell. Biol. 26, 6880-6889 (2006
85. Huynh, K. D., Fischle, W., Verdin, E., & Bardwell, V. J. BCoR, a novel corepressor involved in BCL 6 repression. Genes Dev. 14, 1810-1823 (2000
86. Damm, F., et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 122, 3169-3177 (2013
87. Scheuermann, J. C., et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR DUB. Nature 465, 243-247 (2010
88. Abdel-Wahab, O., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2 mediated gene repression. Cancer Cell 22, 180-193 (2012
89. Balasubramani, A., et al. Cancer-Associated ASXL1 mutations may act as gain of function mutations of the ASXL1-BAP1 complex. Nat. Commun. 6, 7307 (2015
90. Cao, Q., et al. BCOR regulates myeloid cell proliferation and differentiation. Leukemia 30, 1155-1165 (2016
91. Thota, S., et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 124, 1790-1798 (2014
92. Losada, A. Cohesin in cancer: chromosome segregation and beyond. Nat. Rev. Cancer 14, 389-393 (2014
93. Horsfield, J. A., et al. Cohesin-dependent regulation of Runx genes. Development 134, 2639-2649 (2007
94. Leeke, B., Marsman, J., O'Sullivan, J. M., & Horsfield, J. A. Cohesin mutations in myeloid malignancies: underlying mechanisms. Exp. Hematol. Oncol. 3, 13 (2014
95. Marsman, J., et al. Cohesin and CTCF differentially regulate spatiotemporal runx1 expression during zebrafish development. Biochim. Biophys. Acta 1839, 50-61 (2014
96. Mazumdar, C., et al. Leukemia-Associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation. Cell Stem Cell 17, 675-688 (2015
97. Hahn, C. N., et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat. Genet. 43, 1012-1017 (2011
98. Ito, Y., Bae, S. C., & Chuang, L. S. The RUNX family: developmental regulators in cancer. Nat. Rev. Cancer 15, 81-95 (2015
99. Zhang, M. Y., et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat. Genet. 47, 180-185 (2015
100. Growney, J. D., et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106, 494-504 (2005
101. Owen, C. J., et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 112, 4639-4645 (2008
102. Tsai, F. Y., et al. An early haematopoietic defect in mice lacking the transcription factor GATA 2. Nature 371, 221-226 (1994
103. Bejar, R., et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 124, 2705-2712 (2014
104. Rampal, R., et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 9, 1841-1855 (2014
105. Wang, Y., et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol. Cell 57, 662-673 (2015
106. Soenen, V., et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 91, 1008-1015 (1998
107. Rucker, F. G., et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 119, 2114-2121 (2012
108. Lowe, S. W., Cepero, E., & Evan, G. Intrinsic tumour suppression. Nature 432, 307-315 (2004
109. Kaneko, H., Misawa, S., Horiike, S., Nakai, H., & Kashima, K. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 85, 2189-2193 (1995
110. Swisher, E. M., et al. Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. JAMA Oncol. 2, 370-372 (2016
111. Wong, T. N., et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518, 552-555 (2015
112. Zhao, Z., et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 24, 1389-1402 (2010
113. Marusyk, A., Porter, C. C., Zaberezhnyy, V., & DeGregori, J. Irradiation selects for p53 deficient hematopoietic progenitors. PLoS Biol. 8, e1000324 (2010
114. Walter, M. J., et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090-1098 (2012
115. Furitsu, T., et al. Identification of mutations in the coding sequence of the proto-oncogene c kit in a human mast cell leukemia cell line causing ligand-independent activation of c kit product. J. Clin. Invest. 92, 1736-1744 (1993
116. Kottaridis, P. D., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98, 1752-1759 (2001
117. Kralovics, R., et al. A gain of function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005
118. Makishima, H., et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J. Clin. Oncol. 27, 6109-6116 (2009
119. Pardanani, A. D., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108, 3472-3476 (2006
120. Sanada, M., et al. Gain of function of mutated C CBL tumour suppressor in myeloid neoplasms. Nature 460, 904-908 (2009
121. Sargin, B., et al. Flt3 dependent transformation by inactivating c Cbl mutations in AML. Blood 110, 1004-1012 (2007
122. Saur, S. J., Sangkhae, V., Geddis, A. E., Kaushansky, K., & Hitchcock, I. S. Ubiquitination and degradation of the thrombopoietin receptor c Mpl. Blood 115, 1254-1263 (2010
123. Javadi, M., Richmond, T. D., Huang, K., & Barber, D. L. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM CSF) signaling via elevated levels of JAK2 and LYN. J. Biol. Chem. 288, 19459-19470 (2013
124. Haase, D., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110, 4385-4395 (2007
125. Bochtler, T., Frohling, S., & Kramer, A. Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. Leukemia 29, 1243-1252 (2015
126. Bernasconi, P., et al. Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution. Ann. Hematol. 89, 545-551 (2010
127. Wang, H., Wang, X. Q., Xu, X. P., & Lin, G. W. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome. Cancer Genet. Cytogenet. 196, 159-166 (2010
128. Komrokji, R. S., Padron, E., Ebert, B. L., & List, A. F. Deletion 5q MDS: molecular and therapeutic implications. Best practice and research. Clin. Haematol. 26, 365-375 (2013
129. Van den Berghe, H., et al. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251, 437-438 (1974
130. Chen, T. H., et al. Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood 117, 1530-1539 (2011
131. Kumar, M. S., et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q-syndrome. Blood 118, 4666-4673 (2011
132. Starczynowski, D. T., et al. Identification of miR 145 and miR 146a as mediators of the 5q-syndrome phenotype. Nat. Med. 16, 49-58 (2010
133. Stoddart, A., et al. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood 123, 1069-1078 (2014
134. Grisendi, S., et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437, 147-153 (2005
135. Varney, M. E., et al. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor TRAF6 signaling. J. Exp. Med. 212, 1967-1985 (2015
136. DeWard, A. D., Leali, K., West, R. A., Prendergast, G. C., & Alberts, A. S. Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. PLoS ONE 4, e7102 (2009
137. Graubert, T. A., et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PloS ONE 4, e4583 (2009
138. Polprasert, C., et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 27, 658-670 (2015
139. Schneider, R. K., et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26, 509-520 (2014
140. Ebert, B. L., et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451, 335-339 (2008
141. Barlow, J. L., et al. A p53 dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat. Med. 16, 59-66 (2010
142. Schneider, R. K., et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat. Med. 22, 288-297 (2016
143. Ludwig, L. S., et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat. Med. 20, 748-753 (2014
144. Vlachos, A., et al. Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q-syndrome. Blood 122, 2487-2490 (2013
145. Kronke, J., et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 523, 183-188 (2015
146. List, A., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456-1465 (2006
147. Ito, T., et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350 (2010
148. Chen, C., et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25, 652-665 (2014
149. McNerney, M. E., et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 121, 975-983 (2013
150. Nikoloski, G., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665-667 (2010
151. Fenaux, P., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet. Oncol. 10, 223-232 (2009
152. Kantarjian, H., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106, 1794-1803 (2006
153. Traina, F., et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 28, 78-87 (2014
154. Jadersten, M., et al. Clonal heterogeneity in the 5q-syndrome: 53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 94, 1762-1766 (2009
155. Raza, A., et al Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate 1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111, 86-93 (2008
156. Koreth, J., et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J. Clin. Oncol. 31, 2662-2670 (2013
157. Della Porta, M. G., et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J. Clin. Oncol. 30, 3627-3637 (2016
158. Chaturvedi, A., et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122, 2877-2887 (2013
159. Wang, F., et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622-626 (2013
160. Chan, S. M., et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL 2 dependence in acute myeloid leukemia. Nat. Med. 21, 178-184 (2015
161. Fandy, T. E., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5 azacytidine and entinostat in patients with myeloid malignancies. Blood 114, 2764-2773 (2009
162. Lee, S. C., et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat. Med. 22, 672-678 (2016
163. Maxson, J. E., et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N. Engl. J. Med. 368, 1781-1790 (2013
164. Meggendorfer, M., et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 27, 1852-1860 (2013
165. Mason, C. C., et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia 30, 906-913 (2016
166. Lane, A. A., et al. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia 27, 968-971 (2013
167. Shen, W., et al. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 124, 4529-4538 (2014
168. Wilson, D. B., Link, D. C., Mason, P. J., & Bessler, M. Inherited bone marrow failure syndromes in adolescents and young adults. Ann. Med. 46, 353-363 (2014
169. Yamaguchi, H., et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 102, 916-918 (2003
170. Yamaguchi, H., et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N. Engl. J. Med. 352, 1413-1424 (2005
171. Mitchell, J. R., Wood, E., & Collins, K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402, 551-555 (1999
172. Vulliamy, T., et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat. Genet. 36, 447-449 (2004
173. Noetzli, L., et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat. Genet. 47, 535-538 (2015
174. McBride, K. A., et al. Li Fraumeni syndrome: cancer risk assessment and clinical management. Nat. Rev. Clin. Oncol. 11, 260-271 (2014
175. Hsu, A. P., et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 118, 2653-2655 (2011
176. Ostergaard, P., et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat. Genet. 43, 929-931 (2011
177. Lewinsohn, M., et al. Novel germ line DDX41 mutations define families with a lower age of MDS/ AML onset and lymphoid malignancies. Blood 127, 1017-1023 (2016
178. Boocock, G. R., et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat. Genet. 33, 97-101 (2003
179. Zhou, T., Kinney, M. C., Scott, L. M., Zinkel, S. S., & Rebel, V. I. Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research. Blood 126, 1057-1068 (2015
180. Li, Q., et al. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature 504, 143-147 (2013
181. Dolatshad, H., et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia 29, 1798 (2015
182. Chan, C. K., et al. Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature 457, 490-494 (2009
183. Ding, L., Saunders, T. L., Enikolopov, G., & Morrison, S. J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481, 457-462 (2012
184. Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G., & Morrison, S. J. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15, 154-168 (2014
185. Raaijmakers, M. H., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852-857 (2010
186. Kode, A., et al. Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 506, 240-244 (2014
187. Schepers, K., et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285-299 (2013
188. Epperson, D. E., Nakamura, R., Saunthararajah, Y., Melenhorst, J., & Barrett, A. J. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leukemia Res. 25, 1075-1083 (2001
189. Molldrem, J. J., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann. Intern. Med. 137, 156-163 (2002
190. Saunthararajah, Y., Nakamura, R., Wesley, R., Wang, Q. J., & Barrett, A. J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102, 3025-3027 (2003
191. Sloand, E. M., Wu, C. O., Greenberg, P., Young, N., & Barrett, J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J. Clin. Oncol. 26, 2505-2511 (2008
192. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013
193. Patel, J. P., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079-1089 (2012
194. Papaemmanuil, E., et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 374, 2209-2221 (2016
195. Boultwood, J., Dolatshad, H., Varanasi, S. S., Yip, B. H., & Pellagatti, A. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes. Adv. Biol. Regul. 54, 153-161 (2014
196. Fenaux, P., et al A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate 1 risk myelodysplastic syndromes with del5q. Blood 118, 3765-3776 (2011
197. Cordoba, I., et al. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer 118, 127-133 (2012
198. Bacher, U., et al. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. Br. J. Haematol. 164, 822-833 (2014
199. Wang, S. A., et al. Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leuk. Res. 35, 351-357 (2011
200. Wong, A. K., et al. Loss of the Y chromosome: an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome? Arch. Pathol. Lab. Med. 132, 1329-1332 (2008